ADVERTISEMENT

Clinical Summary

Prostate cancer: early androgen blockade delays biochemical progression

Deepa Koli   |   22 November 2022

Takeaway

  • Salvage radiotherapy plus 6-month enzalutamide delays PSA progression in patients with PSA-recurrent high-risk prostate cancer after radical prostatectomy.

Why this matters

  • Clinicians should discuss this approach with patients.

Study design

  • A randomized, double-blind, phase 2, placebo-controlled, multicentre SALV-ENZA study of 86 men with biochemically recurrent prostate cancer who, after ...

          

Topic Challenges

left
right